Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | GLI1 | P08151 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.30 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.30 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25551835 | 1.00 | SCN4A (0.39) | SCN4AGLI1PRCPDPP7TERT | |
| SCHEMBL12214819 | 0.85 | SCN4A (0.41) | SCN4AGLI1PRCPDPP7TERT | |
| SCHEMBL14508102 | 0.85 | SCN4A (0.41) | SCN4AGLI1PRCPDPP7TERT | |
| SCHEMBL11663943 | 0.85 | SCN4A (0.41) | SCN4AGLI1PRCPDPP7 | |
| SCHEMBL14492967 | 0.84 | SCN4A (0.40) | SCN4AGLI1PRCPDPP7DPP4 | |
| SCHEMBL14492971 | 0.84 | SCN4A (0.40) | SCN4AGLI1PRCPDPP7DPP4 | |
| SCHEMBL12214823 | 0.83 | SCN4A (0.39) | SCN4AGLI1PRCPDPP7PFKFB2 | |
| SCHEMBL12214831 | 0.83 | SCN4A (0.39) | SCN4AGLI1PRCPDPP7PFKFB2 | |
| SCHEMBL11659883 | 0.82 | SCN4A (0.39) | SCN4AGLI1PRCPDPP7TERT | |
| SCHEMBL11659292 | 0.81 | SCN4A (0.38) | SCN4AGLI1PRCPDPP7TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230158102-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230158102-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| US-20230158104-A1 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158102-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | ACE, SARS1, ACE2 | SCN4A 1563/4885GLI1 4507/4885PRCP 55/4885 |
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | OAT, MAVS, HAVCR2 | SCN4A 2983/4885GLI1 4382/4885PRCP 1146/4885 |
| US-20230158104-A1 | COMPOUNDS FOR USE IN AUTOIMMUNE CONDITIONS | SSB, HLA-DRB1, TPMT | SCN4A 2938/4885GLI1 3385/4885PRCP 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.